Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

Alireza Eghtedar, Ildefonso Rodriguez, Hagop Kantarjian, Susan O'Brien, Naval Daver, Guillermo Garcia-Manero, Alessandra Ferrajoli, Tapan Kadia, Sherry Pierce, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure.

Original languageEnglish (US)
Pages (from-to)1342-1345
Number of pages4
JournalLeukemia and Lymphoma
Volume56
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Keywords

  • Arsenic
  • Leukemia
  • Promyelocytic
  • Secondary neoplasm

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide'. Together they form a unique fingerprint.

  • Cite this